Atea Pharmaceuticals, Inc. (AVIR) stock
AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.96−0.16 (-3.88%)
Close on Nov 17, 2026Market cap $317.61MP/E –Yield –
Atea Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Atea Pharmaceuticals's total assets was $232.28M at Jun 30, 2026. For fiscal 2025 it was $315.22M, down 32.2% from the year before. The highest annual figure on record is $863.63M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $315.22M | -32.2% |
| FY2024 | Dec 31, 2024 | $464.67M | -21.9% |
| FY2023 | Dec 31, 2023 | $594.97M | -10.8% |
| FY2022 | Dec 31, 2022 | $666.71M | -13.7% |
| FY2021 | Dec 31, 2021 | $772.89M | -10.5% |
| FY2020 | Dec 31, 2020 | $863.63M | +3812.6% |
| FY2019 | Dec 31, 2019 | $22.07M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $232.28M | -40.7% |
| Q1 FY2026 | Mar 31, 2026 | $267.08M | -39.3% |
| Q4 FY2025 | Dec 31, 2025 | $315.22M | -32.2% |
| Q3 FY2025 | Sep 30, 2025 | $342.96M | -30.1% |
| Q2 FY2025 | Jun 30, 2025 | $391.61M | -23.3% |
| Q1 FY2025 | Mar 31, 2025 | $439.96M | -20.4% |
| Q4 FY2024 | Dec 31, 2024 | $464.67M | -21.9% |
| Q3 FY2024 | Sep 30, 2024 | $490.96M | -19.3% |
| Q2 FY2024 | Jun 30, 2024 | $510.38M | -18.5% |
| Q1 FY2024 | Mar 31, 2024 | $553.03M | -13.3% |
| Q4 FY2023 | Dec 31, 2023 | $594.97M | -10.8% |
| Q3 FY2023 | Sep 30, 2023 | $608.08M | -11.4% |
| Q2 FY2023 | Jun 30, 2023 | $626.03M | -9.8% |
| Q1 FY2023 | Mar 31, 2023 | $638.13M | -11.0% |
| Q4 FY2022 | Dec 31, 2022 | $666.71M | -13.7% |
| Q3 FY2022 | Sep 30, 2022 | $686.58M | -18.6% |
| Q2 FY2022 | Jun 30, 2022 | $694.34M | -20.3% |
| Q1 FY2022 | Mar 31, 2022 | $717.19M | -14.7% |
| Q4 FY2021 | Dec 31, 2021 | $772.89M | -10.5% |
| Q3 FY2021 | Sep 30, 2021 | $843.50M | +666.1% |
| Q2 FY2021 | Jun 30, 2021 | $871.54M | +3848.5% |
| Q1 FY2021 | Mar 31, 2021 | $840.65M | – |
| Q4 FY2020 | Dec 31, 2020 | $863.63M | – |
| Q3 FY2020 | Sep 30, 2020 | $110.11M | – |
| Q4 FY2019 | Dec 31, 2019 | $22.07M | – |
See a number that looks wrong?